The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
FGF-21 as a novel metabolic regulator
Open accessAbstract
Diabetes mellitus is a major health concern, affecting more than 5% of the population. Here we describe a potential novel therapeutic agent for this disease, FGF-21, which was discovered to be a potent regulator of glucose uptake in mouse 3T3-L1 and primary human adipocytes. FGF-21-transgenic mice were viable and resistant to diet-induced obesity. Therapeutic administration of FGF-21 reduced plasma glucose and triglycerides to near normal levels in both ob/ob and db/db mice. These effects persisted for at least 24 hours following the cessation of FGF-21 administration. Importantly, FGF-21 did not induce mitogenicity, hypoglycemia, or weight gain at any dose tested in diabetic or healthy animals or when overexpressed in transgenic mice. Thus, we conclude that FGF-21, which we have identified as a novel metabolic factor, exhibits the therapeutic characteristics necessary for an effective treatment of diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In general, FGF21 stimulates the uptake of glucose by adipocytes and inhibits the production of glucose in the liver.”
From Physical Exercise-Induced Myokines and Muscle-Adipose Tissue Crosstalk: A Review of Current Knowledge and the Implications for Health and Metabolic Diseases (2018) · cites this paper as Kharitonenkov et al., 2005
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“FGF21 acts in the control of glucose and lipid homeostasis (Kharitonenkov et al., 2005).”
From Physical Exercise-Induced Myokines and Muscle-Adipose Tissue Crosstalk: A Review of Current Knowledge and the Implications for Health and Metabolic Diseases (2018) · cites this paper as Kharitonenkov et al., 2005
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In addition, FGF21 appears to protect pancreatic β cells from cell death induced by glycotoxicity (Kharitonenkov et al., 2005, 2007).”
From Physical Exercise-Induced Myokines and Muscle-Adipose Tissue Crosstalk: A Review of Current Knowledge and the Implications for Health and Metabolic Diseases (2018) · cites this paper as Kharitonenkov et al., 2005
Experimental — accuracy not yet measuredIn the citing paper
“Interestingly, mice that overexpress FGF-21, a circulating FGF which is induced by a ketogenic diet 106, are lean and have increased brown fat 107, suggesting that the beneficial metabolic effects induced by a ketogenic diet are brought about in part by increases in BAT mass.”
From Cellular bioenergetics as a target for obesity therapy (2010) · cites this paper as [107]
In the citing paper
“FGF21 binding promotes the formation of a dimeric FGFR1c–KLB signalling complex, which activates the intracellular tyrosine kinase domains of FGFR1c and propagates signalling through phosphorylation by the kinase ERK46,53,58,59”
From Metabolic messengers: FGF21 (2021) · cites this paper as [58]
In the citing paper
“prolonged administration of FGF21 or FGF21 analogues has important metabolic effects, including a marked decrease in body weight in rodents and non-human primates, and more modest effects on body weight in humans3,40,58,77,78.”
From Metabolic messengers: FGF21 (2021) · cites this paper as [58]
In the citing paper
“overexpression of FGF21 is highly protective [135].”
From Hepatokines and metabolism: Deciphering communication from the liver (2021) · cites this paper as [135]
In the citing paper
“activation of the FGF21/FGFR1c/KLB receptor complex results in the phosphorylation of ERK1/2 and FRS2α [135].”
From Hepatokines and metabolism: Deciphering communication from the liver (2021) · cites this paper as [135]
In the citing paper
“A myriad of studies ensued demonstrating that administering FGF21 to obese or diabetic rodents and primates markedly reduced body weight and significantly improved carbohydrate and lipid homeostasis (21, 64, 65, 141).”
From Fibroblast Growth Factor 21: A Versatile Regulator of Metabolic Homeostasis (2018) · cites this paper as [64]
In the citing paper
“In rodents, pharmacological levels of FGF21 increase energy expenditure (64, 141), which results in increased food intake (54, 64).”
From Fibroblast Growth Factor 21: A Versatile Regulator of Metabolic Homeostasis (2018) · cites this paper as [64]
In the citing paper
“Since FGF21 administration increases energy expenditure and the browning of adipose tissues in vivo (21, 64, 141), it was hypothesized that FGF21 regulates adaptive thermogenesis in response to cold.”
From Fibroblast Growth Factor 21: A Versatile Regulator of Metabolic Homeostasis (2018) · cites this paper as [64]
In the citing paper
“When administered to diabetic and obese animal models, FGF21 provides multiple metabolic benefits and has been shown to decrease blood glucose levels and body weight, improve insulin and leptin sensitivity, improve plasma lipid profiles, and decrease hepatic steatosis (21, 64, 141, 142).”
From Fibroblast Growth Factor 21: A Versatile Regulator of Metabolic Homeostasis (2018) · cites this paper as [64]
In the citing paper
“Importantly, in animal models FGF21 treatment not only prevents (64) but also reverses diabetes and obesity (21, 141).”
From Fibroblast Growth Factor 21: A Versatile Regulator of Metabolic Homeostasis (2018) · cites this paper as [64]
In the citing paper
“In addition, FGF21 enhances insulin sensitivity in primary brown adipocytes (86) but not in primary white adipocytes (64, 86).”
From Fibroblast Growth Factor 21: A Versatile Regulator of Metabolic Homeostasis (2018) · cites this paper as [64]
In the citing paper
“FGF21’s ability to reduce body weight, glucose levels, and lipid concentrations in models of obesity generated substantial initial interest”
From FGF21 and the physiological regulation of macronutrient preference (2020) · cites this paper as [114]
In the citing paper
“Fibroblast growth factor 21 (FGF21) was first identified as an hepatokine 61 and has been shown to be necessary for the adaptation to fasting 62, 63.”
From Inter‐organ communication: a gatekeeper for metabolic health (2019) · cites this paper as [61]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cell Signaling by Receptor Tyrosine Kinases
Lemmon, M. A., & Schlessinger, J. (2010) · Cell · doi:10.1016/j.cell.2010.06.011 · Cited by 7,929
Global and societal implications of the diabetes epidemic
Zimmet, P., Alberti, K. G. M. M., & Shaw, J. (2001) · Nature · doi:10.1038/414782a · Cited by 5,883
Cell Signaling by Receptor Tyrosine Kinases
Schlessinger, J. (2000) · Cell · doi:10.1016/s0092-8674(00)00114-8 · Cited by 3,774
Ornitz, D. M., & Itoh, N. (2001) · Genome biology · doi:10.1186/gb-2001-2-3-reviews3005 · Cited by 1,985
Frederich, R. C., Hamann, A., Anderson, S., Löllmann, B., Lowell, B. B., & Flier, J. S. (1995) · Nature Medicine · doi:10.1038/nm1295-1311 · Cited by 1,660
Fibroblast growth factors, their receptors and signaling
Powers, C. J., McLeskey, S. W., & Wellstein, A. (2000) · Endocrine-related cancer · doi:10.1677/erc.0.0070165 · Cited by 1,332
Glucose Transporters and Insulin Action — Implications for Insulin Resistance and Diabetes Mellitus
Shepherd, P. R., & Kahn, B. B. (1999) · New England Journal of Medicine · doi:10.1056/nejm199907223410406 · Cited by 1,295
SIGNALLING BY RECEPTOR TYROSINE KINASES
Fantl, W. J., Johnson, D. E., & Williams, L. T. (1993) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.62.1.453 · Cited by 1,118
Cheatham, B., Vlahos, C. J., Cheatham, L. A., Wang, L., Blenis, J., & Kahn, C. R. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.7.4902-4911.1994 · Cited by 1,062
New drug targets for type 2 diabetes and the metabolic syndrome
Moller, D. E. (2001) · Nature · doi:10.1038/414821a · Cited by 1,012
Flagged first, then by citations
Research works printed but not linked: 3
- Konishi, 1999, J. Biol. Chem., 255, 12119
- Shah, 2000, J. Clin. Endocrinol. Metab., 85, 4053
- Cheatham, 1994, Mol. Cell. Biol., 14, 4902, 10.1128/MCB.14.7.4902 · DOI
Cited by
Sorted by citations
Items 701–800 of 1,008
Li, Q., Zhang, Y., Ding, D., Yang, Y., Chen, Q., Su, D., Chen, X., Yang, W., Qiu, J., & Ling, W. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2308 · Cited by 52
Trevino-Villarreal, J. H., Reynolds, J. S., Bartelt, A., Langston, P. K., MacArthur, M. R., Arduini, A., Tosti, V., Veronese, N., Bertozzi, B., Brace, L. E., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.99470 · Cited by 50
Cantó, C., & Auwerx, J. H. (2012) · Science · doi:10.1126/science.1222646 · Cited by 52
Martin, A., Ecklu-Mensah, G., Ha, C. W. Y., Hendrick, G., Layman, D. K., Gilbert, J. A., & Devkota, S. (2021) · Nature Communications · doi:10.1038/s41467-021-24074-z · Cited by 52
Adipokines as Clinically Relevant Therapeutic Targets in Obesity
Würfel, M., Blüher, M., Stümvoll, M., Ebert, T., Kovacs, P. L., Tönjes, A., & Breitfeld, J. (2023) · Biomedicines · doi:10.3390/biomedicines11051427 · Cited by 56
Wu, X., Qi, Y., Chang, J.-R., Lu, W., Zhang, J., Wang, S., Cheng, S., Zhang, M., Fan, Q., Lv, Y., et al. (2014) · Heart and Vessels · doi:10.1007/s00380-014-0557-9 · Cited by 51
Huang, Z., Wang, H., Lu, M., Sun, C., Wu, X., Tan, Y., Ye, C., Zhu, G., Wang, X., Cai, L., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020669 · Cited by 51
Zhang, X., Hu, Y., Zeng, H., Li, L., Zhao, J., Zhao, J., Liu, F., Bao, Y., & Jia, W. (2015) · Cardiovascular Diabetology · doi:10.1186/s12933-015-0190-7 · Cited by 51
FGF21 acts as a negative regulator of bile acid synthesis
Chen, M. M., Hale, C., Stanislaus, S., Xu, J., & Véniant, M. M. (2018) · Journal of Endocrinology · doi:10.1530/joe-17-0727 · Cited by 51
Zanetti, D., Rao, A. S., Gustafsson, S., Assimes, T. L., Montgomery, S. B., & Ingelsson, E. (2019) · Kidney International · doi:10.1016/j.kint.2018.12.017 · Cited by 51
Yang, Q., Shu, F., Gong, J., Ding, P., Cheng, R., Li, J., Tong, R., Ding, L., Sun, H., Huang, W., et al. (2020) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2020.112556 · Cited by 51
Tian, S., Li, X., Wang, Y., & Lu, Y. (2020) · Food Science & Nutrition · doi:10.1002/fsn3.2040 · Cited by 52
Serum levels of angiopoietin-related growth factor in diabetes mellitus and chronic hemodialysis
Ebert, T., Bachmann, A., Lössner, U., Kratzsch, J., Blüher, M., Stümvoll, M., & Faßhauer, M. (2009) · Metabolism · doi:10.1016/j.metabol.2008.11.016 · Cited by 51
Dietary Sulfur Amino Acid Restriction and the Integrated Stress Response: Mechanistic Insights
Jonsson, W. O., Margolies, N., & Anthony, T. G. (2019) · Nutrients · doi:10.3390/nu11061349 · Cited by 51
Ryu, J. Y., Choi, H. M., Yang, H.-I., & Kim, K. S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186887 · Cited by 52
The Role of Lonp1 on Mitochondrial Functions during Cardiovascular and Muscular Diseases
Zanini, G., Selleri, V., Malerba, M., Solodka, K., Sinigaglia, G., Nasi, M., Mattioli, A. V., & Pinti, M. (2023) · Antioxidants · doi:10.3390/antiox12030598 · Cited by 50
Mehdi, S. F., Qureshi, M., Pervaiz, S., Kumari, K., Saji, E., Shah, M., Abdullah, A., Zahoor, K., Qadeer, H., Katari, D. K., et al. (2025) · Molecular Medicine · doi:10.1186/s10020-025-01074-z · Cited by 62
Type VIII Collagen Modulates TGF-β1-induced Proliferation of Mesangial Cells
Loeffler, I., Hopfer, U., Koczan, D., & Wolf, G. (2011) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010010098 · Cited by 51
The regulation of FGF21 gene expression by metabolic factors and nutrients
Erickson, A., & Moreau, R. F. (2016) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2016-0016 · Cited by 53
Liu, X., Zhang, P., Martin, R. C. G., Cui, G., Wang, G., Tan, Y., Cai, L., Lv, G., & Li, Y. (2016) · PubMed Central · Cited by 50
Liver Plays a Major Role in FGF-21 Mediated Glucose Homeostasis
Liu, M., Cao, H., Hou, Y., Sun, G., Li, D., & Wang, W. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000487568 · Cited by 50
Peripheral Mechanisms Mediating the Sustained Antidiabetic Action of FGF1 in the Brain
Scarlett, J. M., Muta, K., Brown, J. M., Rojas, J. M., Matsen, M. E., Acharya, N., Secher, A., Ingvorsen, C., Jørgensen, R., Høeg-Jensen, T., et al. (2018) · Diabetes · doi:10.2337/db18-0498 · Cited by 50
Independent links between plasma xanthine oxidoreductase activity and levels of adipokines
Furuhashi, M., Matsumoto, M., Murase, T., Nakamura, T., Higashiura, Y., Koyama, M., Tanaka, M., Moniwa, N., Ohnishi, H., Saitoh, S., et al. (2018) · Journal of Diabetes Investigation · doi:10.1111/jdi.12982 · Cited by 49
Regulation of Energy Metabolism by Receptor Tyrosine Kinase Ligands
Zhao, M., Jung, Y., Jiang, Z., & Svensson, K. J. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00354 · Cited by 55
Kalinina, J., Byron, S. A., Makarenkova, H. P., Olsen, S. K., Eliseenkova, A. V., LaRochelle, W. J., Dhanabal, M., Blais, S. P., Ornitz, D. M., Day, L. A., et al. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.01780-08 · Cited by 50
Fazeli, P. K., Faje, A. T., Cross, E. J., Lee, H., Rosen, C. J., Bouxsein, M., & Klibanski, A. (2015) · Bone · doi:10.1016/j.bone.2015.04.001 · Cited by 49
Autophagy as a crosstalk mediator of metabolic organs in regulation of energy metabolism
Kim, K. H., & Lee, M. (2013) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-013-9272-6 · Cited by 50
Kim, J. H., Bae, K., Choi, Y. ‐., Go, Y., Choe, M., Jeon, Y. ‐., Lee, H.-M., Koo, S., Perfield, J. W., Harris, R. A., et al. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12408 · Cited by 51
Thompson, W. C., Zhou, Y., Talukdar, S., & Musante, C. J. (2016) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-016-9481-1 · Cited by 49
Jiang, Y., Liu, N., Wang, Q., Yu, Z., Lin, L., Yuan, J., Guo, S., Ahn, B. J., Wang, X., Li, X., et al. (2018) · Stroke · doi:10.1161/strokeaha.118.022119 · Cited by 49
Wu, L., Qian, L., Zhang, L., Zhang, J., Zhou, J., Li, Y., Hou, X., Fang, Q., Li, H., & Jia, W. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.015226 · Cited by 49
Zarei, M., Aguilar-Recarte, D., Palomer, X., & Vázquez‐Carrera, M. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154342 · Cited by 49
Hepatic deficiency of selenoprotein S exacerbates hepatic steatosis and insulin resistance
Qiao, L., Men, L., Yu, S., Yao, J., Li, Y., Wang, M., Yu, Y., Wang, N., Ran, L., Wu, Y., et al. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04716-w · Cited by 50
The Origins, Evolution, and Future of Dietary Methionine Restriction
Fang, H., Stone, K. P., Wanders, D., Forney, L. A., & Gettys, T. W. (2022) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-062320-111849 · Cited by 47
Resident Hepatocyte Fibroblast Growth Factor Receptor 4 Limits Hepatocarcinogenesis
Huang, X., Yang, C., Jin, C., Luo, Y., Wang, F., & Mckeehan, W. (2008) · Molecular Carcinogenesis · doi:10.1002/mc.20494 · Cited by 49
Nonogaki, K., Hazama, M., & Satoh, N. (2014) · BioMed Research International · doi:10.1155/2014/751930 · Cited by 48
Fibroblast growth factor 21: an overview from a clinical perspective
Rydén, M. (2009) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-009-0003-9 · Cited by 48
Zhao, X., Qiao, G., Li, B., Chai, L., Li, Z., Lu, Y., & Yang, B. (2008) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2008.05051.x · Cited by 48
Bernardo, B. L., Lu, M. M., Bandyopadhyay, G. K., Li, P., Zhou, Y., Huang, J. S., Levin, N., Tomás, E., Calle, R. A., Erion, D. M., et al. (2015) · Scientific Reports · doi:10.1038/srep11382 · Cited by 49
Ballestri, S., Nascimbeni, F., Romagnoli, D., Baldelli, E., Targher, G., & Lonardo, A. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17030355 · Cited by 48
Effects of fibroblast growth factor 21 on cell damage in vitro and atherosclerosis in vivo
Zhu, W., Wang, C., Liu, L., Li, Y., Li, X., Cai, J., & Wang, H. (2014) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2014-0227 · Cited by 48
Fgf21 is required for cardiac remodeling in pregnancy
Redondo‐Angulo, I., Mas‐Stachurska, A., Sitges, M., Tinahones, F. J., Giralt, M., Villarroya, F., & Planavila, A. (2017) · Cardiovascular Research · doi:10.1093/cvr/cvx088 · Cited by 48
FGF21 and DPP-4 inhibitor equally prevents cognitive decline in obese rats
Sa‐nguanmoo, P., Tanajak, P., Kerdphoo, S., Jaiwongkam, T., Wang, X., Liang, G., Li, X., Jiang, C., Pratchayasakul, W., Chattipakorn, N., et al. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.12.021 · Cited by 48
Kennelly, J. P., van der Veen, J. N., Nelson, R. C., Leonard, K., Havinga, R., Buteau, J., Kuipers, F., & Jacobs, R. L. (2018) · Journal of Lipid Research · doi:10.1194/jlr.m087056 · Cited by 48
Effect of exercise intensity on circulating hepatokine concentrations in healthy men
Willis, S. A., Sargeant, J. A., Thackray, A. E., Yates, T. E., Stensel, D. J., Aithal, G. P., & King, J. A. (2019) · Applied Physiology, Nutrition, and Metabolism · doi:10.1139/apnm-2018-0818 · Cited by 48
Chen, J., Li, H., Yao, J., Guo, H., Zhang, H., Guo, Y., Sheng, N., Wang, J., & Dai, J. (2021) · Journal of Hazardous Materials · doi:10.1016/j.jhazmat.2020.124963 · Cited by 48
Liu, D., Pang, J., Shao, W., Gu, J., Zeng, Y., He, H. H., Ling, W., Qian, X., & Jin, T. (2021) · Hepatology · doi:10.1002/hep.31856 · Cited by 48
Vienberg, S. G., Brøns, C., Nilsson, E., Astrup, A., Vaag, A., & Andersen, B. (2012) · European Journal of Endocrinology · doi:10.1530/eje-12-0039 · Cited by 47
Xu, L., Li, D., Li, H., Zhang, O., Huang, Y., Shao, H., Wang, Y., Cai, S., Zhu, Y., Jin, S., et al. (2022) · Nutrition and Diabetes · doi:10.1038/s41387-022-00222-2 · Cited by 47
FGF-based drug discovery: advances and challenges
Chen, G., Chen, L., Li, X., & Mohammadi, M. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-01125-w · Cited by 51
FGF21 Mimetic Shows Therapeutic Promise
Reitman, M. L. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.08.014 · Cited by 47
Hydrodynamic delivery of FGF21 gene alleviates obesity and fatty liver in mice fed a high-fat diet
Gao, M., Ma, Y., Cui, R., & Liu, D. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.03.047 · Cited by 48
Anorexia nervosa and bone metabolism
Fazeli, P. K., & Klibanski, A. (2014) · Bone · doi:10.1016/j.bone.2014.05.014 · Cited by 51
Yang, C., Wang, C., Ye, M., Jin, C., He, W., Wang, F., McKeehan, W. L., & Luo, Y. (2012) · Nutrition & Metabolism · doi:10.1186/1743-7075-9-94 · Cited by 48
Agnew, T., Goldsworthy, M. E., Aguilar, C., Morgan, A., Simon, M., Hilton, H., Esapa, C. T., Wu, Y., Cater, H. L., Bentley, L., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.11.080 · Cited by 46
Kim, O. Y., Chung, J. Y., & Song, J. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104411 · Cited by 48
Hepatic hormone FGF21 and its analogues in clinical trials
Shao, W., & Jin, T. (2021) · Chronic Diseases and Translational Medicine · doi:10.1016/j.cdtm.2021.08.005 · Cited by 49
Rao, S., Yang, X., Ohshiro, K., Zaidi, S., Wang, Z., Shetty, K., Xiang, X., Hassan, M. I., Mohammad, T., Latham, P. S., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abk2267 · Cited by 47
Ming, A. Y. K., Yoo, E., Vorontsov, E. N., Altamentova, S. M., Kilkenny, D. M., & Rocheleau, J. V. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.325670 · Cited by 47
Beenken, A., Eliseenkova, A. V., Ibrahimi, O. A., Olsen, S. K., & Mohammadi, M. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.275891 · Cited by 48
(2020) · Advances in clinical chemistry · doi:10.1016/bs.acc.2019.07.012 · Cited by 46
Recent advances in modulators of circadian rhythms: an update and perspective
Huang, S., Jiao, X., Lu, D., Pei, X., Qi, D., & Li, Z. (2020) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2020.1772249 · Cited by 50
Le, T. D. V., Fathi, P. A., Watters, A. B., Ellis, B. J., Besing, G.-L. K., Bozadjieva-Kramer, N., Perez, M. B., Sullivan, A. I., Rose, J. P., Baggio, L. L., et al. (2023) · Molecular Metabolism · doi:10.1016/j.molmet.2023.101718 · Cited by 49
Eto, K., Tumenbayar, B., Nagashima, S., Tazoe, F., Miyamoto, M., Takahashi, M., Ando, A., Okada, K., Yagyu, H., & Ishibashi, S. (2010) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2010.03.019 · Cited by 45
FGF23 contributes to insulin sensitivity in obese adolescents – preliminary results
Wójcik, M., Doleżal-Ołtarzewska, K., Januś, D., Drożdż, D., Sztefko, K., & Starzyk, J. (2011) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2011.04299.x · Cited by 46
Loyd, C., Magrisso, I. J., Haas, M., Balusu, S., Krishna, R., Itoh, N., Sandoval, D. A., Pérez–Tilve, D., Obici, S., & Habegger, K. M. (2016) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00456.2016 · Cited by 49
Corsetti, G., Pasini, E., Scarabelli, T. M., Romano, C., Agrawal, P. R., Chen-Scarabelli, C. A., Knight, R. A., Saravolatz, L. I. I., Narula, J., Ferrari-Vivaldi, M., et al. (2016) · Europe PMC (PubMed Central) · doi:10.11909/j.issn.1671-5411.2016.08.009 · Cited by 48
Santoso, P., Nakata, M., Shiizaki, K., Boyang, Z., Parmila, K., Otgon-Uul, Z., Hashimoto, K., Satoh, T., Mori, M., Kuro‐o, M., et al. (2017) · Scientific Reports · doi:10.1038/srep45819 · Cited by 45
Wang, N., Li, J., Li, S., Guo, X., Wu, T., Wang, W., & Li, D. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.09.143 · Cited by 46
Accuracy of FGF‐21 and GDF‐15 for the diagnosis of mitochondrial disorders: A meta‐analysis
Lin, Y., Ji, K., Ma, X., Liu, S., Li, W., Zhao, Y., & Yan, C. (2020) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51104 · Cited by 48
Yu, J., Zhao, L., Wang, A., Eleswarapu, S., Ge, X., Chen, D., & Jiang, H. (2011) · Endocrinology · doi:10.1210/en.2011-1591 · Cited by 45
Induction of Peroxisomes by Butyrate-Producing Probiotics
Weng, H., Endo, K., Li, J., Kito, N., & Iwai, N. (2015) · PLoS ONE · doi:10.1371/journal.pone.0117851 · Cited by 44
Fang, Q., Li, H., Song, Q., Yang, W. J., Hou, X., Ma, X., Lu, J., Xu, A., & Jia, W. (2013) · Diabetes Care · doi:10.2337/dc12-1766 · Cited by 45
Thiessen, S., Vanhorebeek, I., Derese, I., Gunst, J., & den Berghe, G. V. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2700 · Cited by 45
Maruyama, R., Shimizu, M., Li, J., Inoue, J., & Sato, R. (2016) · Bioscience Biotechnology and Biochemistry · doi:10.1080/09168451.2015.1135045 · Cited by 45
Metabolic actions of fibroblast growth factor 21
Ramos, D. C., Aguilar-Salinas, C. A., & Gomez-Perez, F. J. (2012) · Current Opinion in Pediatrics · doi:10.1097/mop.0b013e3283557d22 · Cited by 46
Zhao, C., Liu, L., Liu, Q., Li, F., Zhang, L., Zhu, F., Shao, T., Barve, S. S., Chen, Y., Li, X., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.08.020 · Cited by 47
Yokote, K., Yamashita, S., Arai, H., Araki, E., Matsushita, M., Nojima, T., Suganami, H., & Ishibashi, S. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01291-w · Cited by 48
Moore, D. D. (2007) · Science · doi:10.1126/science.1144837 · Cited by 45
Erratum: Induction of lipogenesis in white fat during cold exposure in mice: link to lean phenotype
Flachs, P., Adamcová, K., Zouhar, P., Marques, C., Janovská, P., Viegas, I., Jones, J. G., Bardová, K., Svobodová, M., Hansíková, J., et al. (2017) · International Journal of Obesity · doi:10.1038/ijo.2017.61 · Cited by 45
Stemmer, K., Zani, F., Habegger, K. M., Neff, C., Kotzbeck, P., Bauer, M., Yalamanchilli, S., Azad, A., Lehti, M., Martins, P. J. F., et al. (2015) · Diabetologia · doi:10.1007/s00125-015-3668-7 · Cited by 44
Kim, E. R., Kim, S. R., Cho, W., Lee, S., Kim, S. H., Kim, J. H., Choi, E., Kim, J., Yu, J., Lee, B., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.843520 · Cited by 44
Fibroblast growth factor 21 in heart failure
Tucker, W., Tucker, B., Rye, K., & Ong, K. L. (2022) · Heart Failure Reviews · doi:10.1007/s10741-022-10268-0 · Cited by 44
Dietary cysteine drives body fat loss via FMRFamide signaling in Drosophila and mouse
Song, T., Qin, W., Lai, Z., Li, H., Li, D., Wang, B., Deng, W., Wang, T., Wang, L., & Huang, R. (2023) · Cell Research · doi:10.1038/s41422-023-00800-8 · Cited by 49
Toward reconciling the roles of FGF21 in protein appetite, sweet preference, and energy expenditure
Solon‐Biet, S. M., Clark, X., Bell-Anderson, K. S., Rusu, P. M., Perks, R., Freire, T., Pulpitel, T., Senior, A. M., Hoy, A. J., Aung, O., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.113536 · Cited by 43
Maletı́nská, L., Matyšková, R., Maixnerová, J., Sýkora, D., Pýchová, M., Špolcová, A., Blechová, M., Drápalová, J., Lacinová, Z., Haluzı́k, M., et al. (2011) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.06.006 · Cited by 46
Wu, S., Grunwald, T., Kharitonenkov, A., Dam, J., Jockers, R., & Luca, F. D. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.462218 · Cited by 45
RetractedLenart-Lipińska, M., Matyjaszek‐Matuszek, B., Gernand, W., Nowakowski, A. M., & Solski, J. (2013) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2013.04.010 · Cited by 44
Raj, T., Kanellakis, P., Pomilio, G., Jennings, G., Bobik, A., & Agrotis, A. (2006) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000227689.41288.5e · Cited by 44
Metreleptin Improves Blood Glucose in Patients With Insulin Receptor Mutations
Brown, R. J., Cochran, E. K., & Görden, P. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2317 · Cited by 44
Hepatic insulin resistance and increased hepatic glucose production in mice lacking Fgf21
Camporez, J. P., Asrih, M., Zhang, D., Kahn, M., Samuel, V. T., Jurczak, M. J., & Jornayvaz, F. R. (2015) · Journal of Endocrinology · doi:10.1530/joe-15-0136 · Cited by 44
Ghosh, S., Forney, L. A., Wanders, D., Stone, K. P., & Gettys, T. W. (2017) · PLoS ONE · doi:10.1371/journal.pone.0177513 · Cited by 44
Association between Circulating Fibroblast Growth Factor 21 and Aggressiveness in Thyroid Cancer
Kang, Y. E., Kim, J. T., Lim, M. A., Oh, C., Liu, L., Jung, S., Won, H.-R., Lee, K.-M., Chang, J. W., Yi, H., et al. (2019) · Cancers · doi:10.3390/cancers11081154 · Cited by 44
Gao, R.-Y., Hsu, B., Wu, D.-A., Hou, J.-S., & Chen, M.-C. (2019) · International Journal of Endocrinology · doi:10.1155/2019/5163245 · Cited by 46
Watanabe, M., Singhal, G., Fisher, F. M., Beck, T. C., Morgan, D. A., Socciarelli, F., Mather, M. L., Risi, R., Bourke, J., Rahmouni, K., et al. (2019) · Endocrine · doi:10.1007/s12020-019-02124-3 · Cited by 44
Modulatory Effect of Myokines on Reactive Oxygen Species in Ischemia/Reperfusion
Szabó, M. R., Pipicz, M., Csont, T., & Csonka, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249382 · Cited by 45
Gao, J., Liu, J., Meng, Z., Li, Y., Hong, Y., Wang, L., He, L., Hu, B. Q., Zheng, Y., Li, T., et al. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.06.015 · Cited by 44
Nonalcoholic fatty liver disease: Current therapies and future perspectives in drug delivery
Domingues, I., Leclercq, I. A., & Beloqui, A. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.09.040 · Cited by 45
FGF19 promotes progression of prostate cancer
Nagamatsu, H., Teishima, J., Goto, K., Shikuma, H., Kitano, H., Shoji, K., Inoue, S., & Matsubara, A. (2015) · The Prostate · doi:10.1002/pros.22994 · Cited by 43
Teillon, S., Calderon, G. A., & Rios, M. (2010) · Journal of Endocrinology · doi:10.1677/joe-09-0405 · Cited by 44
Metadata
- Authors
- Kharitonenkov, A., Shiyanova, T. L., Koester, A., Ford, A. M., Micanovic, R., Galbreath, E. J., Sandusky, G. E., Hammond, L. J., Moyers, J. S., Owens, R. A., Gromada, J., Brozinick, J. T., Hawkins, E. D., Wroblewski, V. J., Li, D.-S., Mehrbod, F., Jaskunas, S. R., & Shanafelt, A. B.
- Affiliations
- Eli Lilly (United States) (US)
- Corresponding author
- Kharitonenkov, Alexei
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2005-06-01
- Volume
- 115
- Issue
- 6
- Pages
- 1627-1635
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC1088017
- OpenAlex
- W2000665430
- Cited by
- 2,125
- References
- 46
- Citations by year
- 2026: 72 · 2025: 99 · 2024: 111 · 2023: 120 · 2022: 137 · 2021: 138 · 2020: 116 · 2019: 136 · 2018: 147 · 2017: 135 · 2016: 142 · 2015: 155 · 2014: 124 · 2013: 125 · 2012: 115
- FWCI
- 8.78
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Hospital for Sick Children
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fibroblast Growth Factor Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- FGF21, diabetes mellitus, glucose uptake, adipocytes, diet-induced obesity, transgenic mice, ob/ob mice, db/db mice, plasma glucose, triglycerides, metabolic regulation, diabetes treatment
- MeSH terms
- Animals, Blood Glucose, Cell Division, Cells, Cultured, Diabetes Mellitus, Fibroblast Growth Factors, Humans, Hyperglycemia, Hypoglycemic Agents, Mice, Obese, Mice, Transgenic, Triglycerides, Weight Gain, Adipocytes, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
